4.09

3.31% -0.14

Scynexis Inc (SCYX)

Overview News Price History Option Chain Financials Why SCYX Down? Discussions Forecast Stock Split

Scynexis Inc stock is traded at $4.09, with a volume of 48,013. It is down -3.31% in the last 24 hours and down -30.91% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Previous Close:

$4.23

Open:

$4.25

24h Volume:

48,013

Relative Volume:

0.67

Market Cap:

$40.62M

Revenue:

$20.34M

Net Income/Loss:

$-24.52M

P/E Ratio:

-1.1437

EPS:

-3.5761

Net Cash Flow:

$-5.92M

1W Performance:

-8.09%

1M Performance:

-30.91%

6M Performance:

-19.82%

1Y Performance:

-36.69%

1-Day Range:

$4.09

$4.37

1-Week Range:

$4.09

$4.75

52-Week Range:

$4.09

$10.48

Scynexis Inc Stock (SCYX) Company Profile

Name

Scynexis Inc

Sector

Healthcare (1104)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

201-884-5485

Address

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Employee

Twitter

@scynexis

Next Earnings Date

2026-05-21

Latest SEC Filings

SCYX's Discussions on Twitter

Compare SCYX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCYX Scynexis Inc	4.09	40.62M	20.34M	-24.52M	-5.92M	-3.5761
TAK Takeda Pharmaceutical Co Adr	15.77	49.83B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.07	40.04B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.69	39.23B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	79.95	33.52B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	549.57	23.33B	3.17B	1.29B	1.01B	27.09

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-21	Initiated	Guggenheim	Buy
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-18	Upgrade	Needham	Hold → Buy
Jun-27-18	Initiated	Maxim Group	Buy
Oct-24-17	Initiated	Guggenheim	Buy
Jul-10-17	Initiated	ROTH Capital	Buy
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform
Oct-20-16	Initiated	H.C. Wainwright	Buy
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy
Aug-09-16	Reiterated	Needham	Buy
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy
Mar-28-16	Initiated	Brean Capital	Buy
Dec-29-15	Initiated	WBB Securities	Speculative Buy
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform
Jun-10-15	Initiated	Needham	Buy
May-29-14	Initiated	Canaccord Genuity	Buy
May-29-14	Initiated	RBC Capital Mkts	Outperform

View All

Scynexis Inc Stock (SCYX) Latest News

Jun 14, 2026

SCYNEXIS (SCYX) Holds Near Support Amid Quiet TradingFast Moving Stocks - newsline.com

Jun 14, 2026

SCYNEXIS Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueInvestor Earnings Call - newsline.com

Jun 14, 2026

Jun 13, 2026

SCYNEXIS, Inc. Hits New 52-Week High of $5.62, Up 157.49% - MarketsMojo

Jun 13, 2026

Jun 12, 2026

SCYNEXIS (SCYX) Picks Up Slightly as Stock Bounces Within Established RangeDiagonal Spread Trade - newsline.com

Jun 12, 2026

Jun 09, 2026

SCYNEXIS (SCYX) Slides 2.6% as Stock Approaches Key SupportATR Trailing Stop - newsline.com

Jun 09, 2026

Jun 04, 2026